Aug. 19 at 12:38 PM
$ARCT $MRNA After great mRNA cancer immunotherapy results from Moderna I want to highlight the oncology potential of the sa-mRNA technology developed by Arcturus Therapeutics:
"We assessed the levels of CD8+ T cells expression PD-1 or Lag-3, well characterized exhaustion markers, and found significantly lower levels of exhaustion markers in mice vaccinated with sa-mRNA compared to conventional mRNA (Figure 8C). We hypothesize that the additional innate immune stimulation from the replicase intermediates may be responsible for the reduction in exhaustion markers. (...) Altogether, our data indicate that our STARR platform not only delivers a higher magnitude of epitope-specific responses compared to conventional mRNA, but that the T cell response induced by the STARR platform is better suited for clinical efficacy even after multiple vaccinations by inducing highly functional and cytotoxic T cells with the relevant memory markers (Tem)."
https://ir.arcturusrx.com/static-files/a0d627a6-e362-4e2b-a506-1474c33da288
